Core Insights - The article highlights the successful completion of the GLORY-2 Phase III clinical trial for the world's first GCG/GLP-1 dual receptor agonist, Masitide, developed by Innovent Biologics, targeting severe obesity in China [1][2][3] - The trial demonstrated significant weight loss and improvements in various metabolic parameters among participants with a BMI ≥ 30 kg/m², indicating a potential new treatment option for a population lacking effective pharmacological interventions [1][2] Group 1: Clinical Trial Results - The GLORY-2 study included 462 participants with simple obesity and obesity combined with diabetes, randomized in a 2:1 ratio to receive either Masitide 9mg or a placebo for 60 weeks [2] - Results showed that the Masitide 9mg group achieved significant weight loss compared to the placebo group, along with reductions in waist circumference, systolic blood pressure, triglycerides, non-HDL cholesterol, LDL cholesterol, and uric acid levels [2] Group 2: Market Potential and Regulatory Plans - Innovent Biologics plans to submit a marketing application for Masitide 9mg to the National Medical Products Administration (NMPA) for adult weight control [3] - The development of Masitide 9mg specifically addresses the weight management needs of patients with a BMI greater than 30 kg/m², particularly those above 32.5 kg/m², who previously relied on surgical interventions for effective weight management [3]
信达生物公布玛仕度肽GLORY-2数据